Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Maintenance dose: 0.75 to 1.5 mg subcutaneously once a week
Dosing, duration, monitoring, and adjustment guidelines
This pharmacokinetic profile is not influenced by gallbladder status
Three key findings result from our study: (1) pwIIH treated with GLP-1-RAs lose significantly more weight than pwIIH electing for UCWM only, (2) treatment with GLP-1-RAs is associated with favorable headache outcomes, and (3) treatment with GLP-1-RAs is not associated with any severe adverse events in IIH, and thus presents a safe treatment option for weight management in pwIIH
, 2008, vol
US$ 20.14
US$ 21.34
US$ 22.18
US$ 20.97
